Advertisement


Jonathan W. Riess, MD, on EGFR-Mutated Non–Small Cell Lung Cancer: What’s Next?

2023 ASCO Annual Meeting

Advertisement

Jonathan W. Riess, MD, of the University of California, Davis Comprehensive Cancer Center, explores the findings of three important clinical trials in lung cancer treatment: whether to incorporate immune checkpoint inhibitors into the treatment of EGFR-mutated lung cancer, the importance of central nervous system activity in EGFR-mutant lung cancer, and new therapies for disease with EGFR exon 20 insertion.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Jonathan W. Riess, MD: At this ASCO 2023 annual meeting, I'm speaking on EGFR-mutated non-small cell lung cancer: What's next? And I'll be discussing three important abstracts that will be presented at the oral session for metastatic non-small cell lung cancer. The first abstract is KEYNOTE 789, which is adding pembrolizumab immunotherapy to platinum pemetrexed based chemotherapy. It's a clinical trial that randomizes patients with advanced EGFR-mutated non-small cell lung cancer who've progressed on prior EGFR tyrosine kinase inhibitor to either chemotherapy or chemotherapy plus pembrolizumab. And this is an important study because patients with EGFR-mutated non-small cell lung cancer were excluded from many of the pivotal chemo-immunotherapy clinical trials in the past, because we think of these tumors as being less responsive to single agent immunotherapy. And in this study there was no clear progression-free survival or overall survival benefit with the addition of pembrolizumab to platinum pemetrexed based chemotherapy. This study highlights the importance of better selecting patients with EGFR-mutated non-small cell lung cancer for that small population that might benefit from immunotherapy or immune checkpoint inhibitor combinations, as well as, other potential factors that may potentiate the immune response. Within this study, it looked like patients whose tumors had positive PD-L1 expression might do slightly better, but once again, no overall survival or progression-free survival benefit was shown. So it is not clear and it does not show that immunotherapy added to chemotherapy provides any benefit to these patients. There are further studies looking at the combination of immunotherapy with anti-angiogenesis agents in combination with chemotherapy, and there may be some potentiation of immune activity with that anti-angiogenesis immunotherapy ICI interaction. But we still have yet to see an overall survival benefit from studies already conducted, and we eagerly await the results of future studies. For the second abstract I will be discussing, it's zorifertinib in EGFR-mutant non-small cell lung cancer. This trial, conducted in Asia, randomized patients to a highly CNS penetrant, EGFR TKI zorifertinib versus first-generation EGFR TKI erlotinib or gefitinib. And in this study for patients with treatment-naive EGFR-mutant non-small cell lung cancer with active untreated asymptomatic brain metastases, zorifertinib improved progression-free survival compared to erlotinib or gefitinib and also had an increased PFS in terms of intracranial progression. Now, osimertinib is also an EGFR tyrosine kinase inhibitor with high CNS penetration and has shown a progression-free survival and overall survival benefit compared to gefitinib or erlotinib. But this drug may not be available at all places in the world, although it's the standard of care in the United States. And so, it's unclear right now if this will change the standard of care of the future because of osimertinib being used in the first-line setting in the United States and Europe in many parts of the world. The third abstract I'll be discussing is sunvozertinib and EGFR Exon 20 insertion non-small cell lung cancer. These are uncommon EGFR-mutations, yet important ones. They're the third most common EGFR activating mutation. About 10 to 12% of EGFR-mutated non-small cell lung cancer. And there's been a number of advances recently with the FDA approval of amivantamab and mobocertinib after progression on platinum-based chemotherapy. Sunvozertinib was studied in the WU-KONG6 study, which I will be discussing, and that showed, in patients who have had prior treatment for EGFR Exon 20 insertion non-small cell lung cancer, a response rate of 60.8%, which looks favorable in the context of other recently approved Exon 20 agents such as amivantamab and mobocertinib. Sunvozertinib has favorable activity with response rate of 60.8% in the WU-KONG6 trial. It also appears to have CNS activity, which is important and compares very favorably to current FDA approved agents amivantamab and mobocertinib. Some unanswered questions are the sequencing of Exon 20 agents, as well as, potential combinations strategies in the future, but this looks like to be an exciting drug that's being developed further.

Related Videos

Leukemia

Sarah K. Tasian, MD, on Hematologic Malignancies in Children: Expert Commentary

Sarah K. Tasian, MD, of Children’s Hospital of Philadelphia, summarizes three studies presented at ASCO: genomic determinants of outcome in acute lymphoblastic leukemia (ALL), a phase III trial of inotuzumab ozogamicin for high-risk B-cell ALL, and preliminary results from the first-in-child phase II trial of bosutinib in pediatric patients with newly diagnosed chronic myeloid leukemia (Abstracts 10015, 10016, and 10017).

Myelodysplastic Syndromes
Supportive Care

Aaron T. Gerds, MD, on Anemia in Myelofibrosis: New Data on Treatment With Luspatercept

Aaron T. Gerds, MD, of Cleveland Clinic Taussig Cancer Institute, talks about treating the anemia many patients with myelofibrosis experience because of JAK inhibitor therapy. The ACE-536-MF-001 study showed that luspatercept improved anemia and transfusion burden in this population, with a safety profile consistent with that in previous studies (Abstract 7016).

Leukemia

LaQuisa C. Hill, MD, on Relapsed or Refractory T-ALL: New Data on CD5 CAR T Cells

LaQuisa C. Hill, MD, of Baylor College of Medicine, Houston Methodist Hospital, discusses study findings showing that CD5 chimeric antigen receptor (CAR) T cells may induce clinical responses in heavily treated patients with relapsed or refractory T-cell acute lymphoblastic leukemia. Manufacturing CD5 CAR T cells with tyrosine kinase inhibitors seemed to improve their potency and antitumor activity (Abstract 7002).

Lung Cancer

Nagla Abdel Karim, MD, on Small Cell Lung Cancer: SWOG S1929 Results on Atezolizumab Plus Talazoparib

Nagla Abdel Karim, MD, of the Inova Schar Cancer Institute, University of Virginia, discusses phase II data showing that maintenance atezolizumab plus talazoparib improved progression-free survival in Schlafen-11–selected patients with extensive-stage small cell lung cancer. This study demonstrated the feasibility of conducting biomarker-selected trials in this disease, paving the way for future evaluation of novel therapies in selected populations (Abstract 8504).

Lymphoma

Manali K. Kamdar, MD, on Primary Refractory and Early Relapsing DLBCL: Therapeutic Options

Manali K. Kamdar, MD, of University of Colorado Hospital, discusses the treatment landscape for the 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) whose disease will relapse. Patients who experience relapse within 1 year of chemoimmunotherapy have poor outcomes with autotransplantation, but chimeric antigen receptor T-cell therapy has shown efficacy and manageable toxicity.

Advertisement

Advertisement




Advertisement